Ropes Wealth Advisors LLC reduced its stake in Novartis AG (NYSE:NVS) by 5.3% during the fourth quarter, according to its most recent filing with the SEC. The fund owned 5,066 shares of the company’s stock after selling 286 shares during the quarter. Ropes Wealth Advisors LLC’s holdings in Novartis were worth $435,000 at the end of the most recent quarter.
Several other large investors also recently modified their holdings of NVS. AlphaMark Advisors LLC acquired a new stake in shares of Novartis in the 4th quarter worth approximately $30,000. Laurel Wealth Advisors LLC purchased a new stake in shares of Novartis during the 4th quarter worth approximately $35,000. Sonora Investment Management LLC raised its holdings in shares of Novartis by 93.9% during the 4th quarter. Sonora Investment Management LLC now owns 479 shares of the company’s stock worth $41,000 after acquiring an additional 232 shares in the last quarter. Cornerstone Advisors Inc. raised its holdings in shares of Novartis by 89.4% during the 3rd quarter. Cornerstone Advisors Inc. now owns 502 shares of the company’s stock worth $43,000 after acquiring an additional 237 shares in the last quarter. Finally, Lavaca Capital LLC purchased a new stake in shares of Novartis during the 4th quarter worth approximately $48,000. 11.56% of the stock is currently owned by institutional investors.
Several analysts have recently issued reports on the company. JPMorgan Chase & Co. reaffirmed a “sell” rating on shares of Novartis in a report on Tuesday, January 29th. Credit Suisse Group lowered Novartis to a “sell” rating in a research note on Thursday, December 20th. Zacks Investment Research raised Novartis from a “hold” rating to a “buy” rating and set a $96.00 target price on the stock in a research report on Tuesday, December 18th. Jefferies Financial Group reiterated a “buy” rating and issued a $105.00 price target on shares of Novartis in a report on Tuesday, December 11th. Finally, Barclays downgraded Novartis from an “equal weight” rating to a “sell” rating in a research note on Friday, December 7th. Three equities research analysts have rated the stock with a sell rating, six have assigned a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the company. Novartis currently has an average rating of “Hold” and an average target price of $90.94.
Novartis (NYSE:NVS) last issued its quarterly earnings results on Wednesday, January 30th. The company reported $1.24 earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of $1.33 by ($0.09). The firm had revenue of $13.27 billion during the quarter, compared to analyst estimates of $13.33 billion. Novartis had a return on equity of 15.66% and a net margin of 24.30%. The firm’s revenue for the quarter was up 2.7% on a year-over-year basis. During the same quarter last year, the firm posted $1.21 EPS. Equities research analysts expect that Novartis AG will post 5.43 EPS for the current year.
The company also recently declared an annual dividend, which will be paid on Wednesday, March 13th. Stockholders of record on Tuesday, March 5th will be given a $2.8646 dividend. The ex-dividend date of this dividend is Monday, March 4th. This represents a dividend yield of 3.27%. This is an increase from Novartis’s previous annual dividend of $2.33. Novartis’s payout ratio is 37.52%.
Novartis Company Profile
Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company's Innovative Medicines segment offers patented prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology and dermatology, respiratory, cardio-metabolic, and established medicine products.
Further Reading: Cost of Goods Sold (COGS)
Want to see what other hedge funds are holding NVS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Novartis AG (NYSE:NVS).
Receive News & Ratings for Novartis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novartis and related companies with MarketBeat.com's FREE daily email newsletter.